This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Idenix Pharmaceuticals' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Idenix Pharmaceuticals (IDIX)

Presentation at Morgan Stanley Global Healthcare Conference

September 10, 2012 1:15 p.m. ET

Executives

Ronald Renaud - President and CEO

Douglas Mayers - EVP and Chief Medical Officer

Analysts

David Friedman - Morgan Stanley

Presentation

David Friedman - Morgan Stanley

Thanks everyone for joining. Dave Friedman, biotech analyst here at Morgan Stanley. And for disclosure purposes, Morgan Stanley as well as personal holdings disclosures are available at morganstanley.com/researchdisclosures.

And I’m happy to have the team from Idenix up here. On the far side, Doug Mayers, chief medical officer; and on the nearside, Ron Renaud, president and CEO. And we’d look for this to be interactive and so any questions, anyone feel free to raise their hand. We’ll make sure we get to you. If I don’t see you, just yell or something and we’ll make sure.

My guess is most people know the company, but maybe for the one or two that don’t, if you can just give a couple minute overview of who you guys are and what you guys have going on?

Ronald Renaud

First of all, thanks for having us. Idenix is a company focused on developing antivirals. Right now our singular focus is on direct-acting antivirals for the treatment of hepatitis C. We have taken a nucleoside across the finish line in hepatitis B, and that drug is now sold by Novartis. We did that in our previous collaboration with Novartis, and that drug is now on the market and sold in more than 60 countries worldwide.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs